Leerink Partnrs Has Bullish Forecast for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Edwards Lifesciences in a report released on Wednesday, December 4th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings of $0.60 per share for the quarter, up from their previous estimate of $0.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.62 EPS and FY2027 earnings at $3.29 EPS.

Several other brokerages also recently issued reports on EW. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday. Evercore ISI cut their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Citigroup dropped their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.35.

Edwards Lifesciences Trading Down 2.4 %

Shares of EW stock opened at $72.43 on Friday. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a market capitalization of $42.72 billion, a P/E ratio of 10.45, a P/E/G ratio of 3.95 and a beta of 1.12. The firm has a 50-day moving average price of $68.55 and a 200 day moving average price of $74.76. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. The firm’s revenue was up 8.9% on a year-over-year basis.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $2,657,000 in the last ninety days. 1.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after buying an additional 40,348 shares during the period. Raymond James & Associates lifted its holdings in Edwards Lifesciences by 2.8% in the second quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after buying an additional 50,124 shares during the period. AIA Group Ltd lifted its holdings in Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after buying an additional 358,556 shares during the period. RiverPark Advisors LLC lifted its holdings in Edwards Lifesciences by 58.1% in the third quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock valued at $1,362,000 after buying an additional 7,583 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its holdings in Edwards Lifesciences by 40.0% in the second quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company’s stock valued at $3,394,000 after buying an additional 10,492 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.